Welcome to our dedicated page for Mural Oncology PLC SEC filings (Ticker: MURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mural Oncology plc's SEC filings document material-event disclosures for a former Nasdaq-listed Irish biotechnology issuer, including Forms 8-K reporting operating results, financial condition, material agreements, shareholder voting matters, governance matters, and capital-structure information tied to its ordinary shares.
The filing record also covers corporate-status and transaction disclosures associated with its completed Irish scheme of arrangement and acquisition. These records describe formal shareholder materials, registered security information, exhibit filings, and clinical, regulatory, and operating disclosures relevant to Mural's cytokine-based immunotherapy business history.
Trium Capital LLP filed an SEC Form 3 disclosing initial beneficial ownership in Mural Oncology plc (MURA US). The filing reports 1,760,097 shares of MURA held directly. The event date listed is 08/22/2025 and the form is signed by Fredrik Ostlund on 09/02/2025. The filing identifies the reporting person as a Director.
Mural Oncology plc disclosed a transaction agreement dated August 20, 2025, among Mural Oncology plc, XOMA Royalty Corporation and XRA 5 Corp. The filing describes mutual termination rights: the Company may terminate if the bidder breaches material covenants or if the Board approves a Superior Proposal before shareholder approval; the bidder may terminate for the Companys material breach, a Board change in recommendation, or if the Company solicits a Superior Proposal and does not cure within 15 days.
The filing also includes customary forward-looking disclaimers and lists related exhibits and communications, including a Rule 2.7 announcement, Rule 2.10 letters to shareholders and employees, a directors irrevocable undertaking, and the transaction agreement as exhibits. The disclosures focus on deal mechanics and termination conditions rather than financials.
Mural Oncology plc received a joint Schedule 13G/A from Armistice Capital, LLC and Steven Boyd reporting that the reporting persons do not beneficially own any ordinary shares of the issuer. The filing states zero shares owned and 0% of the class based on 17,324,359 shares outstanding as reported by the issuer.
The filing explains that Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice Capital exercises voting and investment power over the Master Fund's securities. The Master Fund disclaims beneficial ownership due to its inability to vote or dispose of the securities under the investment management agreement. The Master Fund retains the right to receive dividends or sale proceeds.
Mural Oncology plc received an amended Schedule 13G filing from Solas Capital Management, LLC and Frederick Tucker Golden reporting that neither the adviser nor Mr. Golden beneficially own any ordinary shares of the company. The filing lists the issuer's Dublin address and the security CUSIP G63365103. Both reporting parties state 0 shares owned and 0.0% of the class, and clarify the adviser relationship to private funds while noting the funds disclaim beneficial ownership. Signatures by Frederick Tucker Golden certify the accuracy of the statement.